The synergistic effect of elacridar with imatinib re-sensitized imatinib-resistant cell lines expressing BCRP and P-gp in chronic myeloid leukemia (CML) [48]. This evidence concerns the gene ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive.